BLTE · Insider Trading

Belite Bio, Inc American Depositary Shares

Every open-market purchase and sale reported by BLTE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Form 4 Filings
36
most recent
Open-Market Buys
0
code P
Sales
26
code S
Reporting Insiders
4
current holders
BLTE — Recent Form 4 Transactions (latest 2026-10-30)
FiledInsiderRole TypeSharesValue
2026-10-30 Yu-Hsin Lin Chief Executive Officer J +5,000 —
2026-10-30 Wan-Shan Chen Director X +13,796 +$6.05K
2026-10-30 Hao-Yuan Chuang Chief Financial Officer J +5,000 —
2026-10-05 Hendrik Peter Scholl Chief Medical Officer Sell −500 −$82.66K
2026-09-09 Hao-Yuan Chuang Chief Financial Officer Sell −67,395 −$12.80M
2026-09-09 Yu-Hsin Lin Chief Executive Officer Sell −100,435 −$19.08M
2026-08-14 Hao-Yuan Chuang Chief Financial Officer Sell −367 −$66.19K
2026-08-14 Yu-Hsin Lin Chief Executive Officer Sell −365 −$65.83K
2026-06-22 Hendrik Peter Scholl Chief Medical Officer Sell −10,000 −$1.45M
2026-06-17 Hendrik Peter Scholl Chief Medical Officer Sell −10,000 −$1.41M
2026-05-08 Nathan L. Mata Chief Scientific Officer Sell −666 −$102.04K
2026-05-07 Nathan L. Mata Chief Scientific Officer Sell −1,000 −$153.84K
2026-05-06 Nathan L. Mata Chief Scientific Officer Sell −1,000 −$155.50K
2026-05-05 Nathan L. Mata Chief Scientific Officer Sell −1,000 −$155.64K
2026-05-04 Nathan L. Mata Chief Scientific Officer Sell −1,000 −$155.78K
2026-05-01 Nathan L. Mata Chief Scientific Officer Sell −1,000 −$156.97K
2026-04-29 Nathan L. Mata Chief Scientific Officer Sell −1,000 −$159.16K
2026-04-28 Nathan L. Mata Chief Scientific Officer Sell −1,000 −$162.64K
2026-04-27 Nathan L. Mata Chief Scientific Officer Sell −1,000 −$159.56K
2026-04-24 Nathan L. Mata Chief Scientific Officer Sell −1,000 −$166.28K
2026-04-23 Yu-Hsin Lin Chief Executive Officer J +10,000 —
2026-04-23 Hendrik Peter Scholl Chief Medical Officer J +10,000 deriv. —
2026-04-23 Hao-Yuan Chuang Chief Financial Officer J +10,000 —
2026-04-23 Nathan L. Mata Chief Scientific Officer Sell −1,000 −$170.38K
2026-04-22 Nathan L. Mata Chief Scientific Officer Sell −1,000 −$166.00K
2026-04-21 Nathan L. Mata Chief Scientific Officer Sell −1,000 −$163.59K
2026-04-20 Nathan L. Mata Chief Scientific Officer Sell −1,000 −$161.63K
2026-04-20 Nathan L. Mata Chief Scientific Officer Sell −1,000 −$160.38K
2026-04-16 Nathan L. Mata Chief Scientific Officer Sell −1,000 −$168.30K
2026-04-13 Wan-Shan Chen Director Sell −1,100 −$198.47K
2026-04-13 Hao-Yuan Chuang Chief Financial Officer Sell −6,200 −$1.13M
2026-04-13 Yu-Hsin Lin Chief Executive Officer Sell −9,200 −$1.67M
2026-04-02 Nathan L. Mata Chief Scientific Officer A +144,868 deriv. —
2026-04-02 Wan-Shan Chen Director A +13,796 deriv. —
2026-04-02 Hao-Yuan Chuang Chief Financial Officer A +144,868 deriv. —
2026-04-02 Yu-Hsin Lin Chief Executive Officer A +206,954 deriv. —
BLTE — Current Insider Holders
InsiderRole Shares HeldValue
Hao-Yuan Chuang Chief Financial Officer 210,264 $32.11M
Yu-Hsin Lin Chief Executive Officer 187,949 $28.70M
Wan-Shan Chen Director 37,259 $5.69M
Hendrik Peter Scholl Chief Medical Officer 14,500 $2.21M
BLTE Insider Trading FAQ
Who are the insiders at BLTE?
4 officers, directors and 10%+ beneficial owners currently report holdings in BLTE via SEC Form 4.
Are BLTE insiders buying or selling?
Across the 36 most recent Form 4 filings for BLTE, 0 were open-market purchases (code P) and 26 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is BLTE insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent BLTE filing is dated 2026-10-30.
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the BLTE quote page; the site-wide leaderboard is on the insider transactions hub.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.